Advocacy intelligence hub — real-time data for patient organizations
Mediar Therapeutics — PHASE1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — PHASE2
Regeneron Pharmaceuticals — PHASE2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chinese PLA General Hospital — PHASE4
Sohag University — NA
Shoichi Maruyama MD PhD — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Non-genetic systemic disease with glomerulopathy as a major feature news →
View all Non-genetic systemic disease with glomerulopathy as a major feature specialists →